Advertisement

Opportunities to Optimize Cancer Policies Panel Discussion

First International Summit on Interventional Pharmacoeconomics

Advertisement


Related Videos

Deborah Collyar: What's In It for Patients?

Victoria T. Brown, PharmD, BCOP, on Payer Intervention: The Example of Abiraterone

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

Advertisement

Advertisement



Jan
21
Today In Oncology
Patient-Reported Outcomes With Triplet Therapy for Newly Diagnosed Multiple Myeloma
Surgical Intervention May Offer Survival Advantage for Certain Patients With Metastatic Breast Cancer
Do Adult-Onset Cancer Survivors Have a Higher Risk of Developing a Subsequent Malignancy
Adjuvant Gefitinib vs Vinorelbine/Cisplatin in Stage II–IIIA EGFR-Mutant NSCLC
Study Finds Inflammation Due to Androgen-Deprivation Therapy May Contribute to Fatigue, Other Side Effects in Men With Prostate Cancer
View More 
Advertisement
© 2021 HSP News Service, L.L.C.
Designed by Harborside